"NPJ Vaccines"[ Journal] - Search Results

Year	Number of Results
2016	16
2017	36
2018	55
2019	54
2020	112
2021	158
2022	174
2023	190
2024	238

1

Mass cytometry reveals cellular correlates of immune response heterogeneity to SARS-CoV-2 vaccination in the elderly.

Mukherjee R, Eggesbø LM, Wolf AS, Kjønstad IF, Solum G, Ravussin A, Bhandari S, Robertson AH, Magnus P, Trogstad L, Kristoffersen AB, Nygaard UC, Mjaaland S. Mukherjee R, et al. NPJ Vaccines. 2024 Nov 29;9(1):238. doi: 10.1038/s41541-024-01028-2. NPJ Vaccines. 2024. PMID: 39613759 Free PMC article.

2

Evaluation of one year immunity following rabies post-exposure prophylaxis in dog bite cases.

Ya N, Auerswald H, Touch S, In S, Yun C, Thai P, Sann S, Heng B, Leng C, Duong V, Peng YS, Ly S, Cantaert T. Ya N, et al. NPJ Vaccines. 2024 Nov 27;9(1):237. doi: 10.1038/s41541-024-01030-8. NPJ Vaccines. 2024. PMID: 39604401 Free PMC article.

3

Modi-2 a vaccine stimulating CD4 responses to homocitrullinated self epitopes as therapy for solid cancers.

Al-Omari AA, Cook KW, Symonds P, Skinner A, Wright A, Zhu Y, Coble VL, Mohammed OJ, Choudhury RH, Uddin N, Ranglani P, Parry A, Adams SE, Lynn GM, Durrant LG, Brentville VA. Al-Omari AA, et al. NPJ Vaccines. 2024 Nov 27;9(1):236. doi: 10.1038/s41541-024-01029-1. NPJ Vaccines. 2024. PMID: 39604380 Free PMC article.

4

Author Correction: Reply to: mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination.

Li JX, Wang YH, Bair H, Hsu SB, Chen C, Wei JC, Lin CJ. Li JX, et al. NPJ Vaccines. 2024 Nov 25;9(1):234. doi: 10.1038/s41541-024-01026-4. NPJ Vaccines. 2024. PMID: 39587115 Free PMC article. No abstract available.

5

Ad26.RSV.preF completely protects calves from severe respiratory disease induced by bovine RSV challenge.

van der Fits L, de Jong R, Dijkman K, Heemskerk-van der Meer M, Tettero L, Bonsing J, van Oort S, Serroyen J, van Schie M, Stockhofe-Zurwieden N, Callendret B, Zahn R. van der Fits L, et al. NPJ Vaccines. 2024 Nov 25;9(1):235. doi: 10.1038/s41541-024-01024-6. NPJ Vaccines. 2024. PMID: 39587114 Free PMC article.

6

A randomized trial comparing safety, immunogenicity and efficacy of self-amplifying mRNA and adenovirus-vector COVID-19 vaccines.

Ho NT, Hughes SG, Sekulovich R, Ta VT, Nguyen TV, Van Pham AT, Luong QC, Le Tran LT, Van Luu AT, Nguyen AN, Pham HT, Nguyen VT, Berdieva D, Bugarini R, Liu X, Verhoeven C, Smolenov I, Nguyen XH. Ho NT, et al. NPJ Vaccines. 2024 Nov 23;9(1):233. doi: 10.1038/s41541-024-01017-5. NPJ Vaccines. 2024. PMID: 39580505 Free PMC article.

7

The PvRBP2b-TfR1 interaction is not essential for reticulocytes invasion by Plasmodium vivax isolates from Cambodia.

Feufack-Donfack LB, Baldor L, Roesch C, Tat B, Orban A, Seng D, Salvador J, Khim N, Carias L, King CL, Russell B, Nosten F, Ong AS, Mao H, Renia L, Lo E, Witkowski B, Popovici J. Feufack-Donfack LB, et al. NPJ Vaccines. 2024 Nov 22;9(1):232. doi: 10.1038/s41541-024-01031-7. NPJ Vaccines. 2024. PMID: 39578462 Free PMC article.

8

Effect of XBB.1.5-adapted booster vaccination on the imprinting of SARS-CoV-2 immunity.

Pušnik J, Monzon-Posadas WO, Osypchuk E, Dubiel AE, Baum M, Fehring P, Büning A, Klant T, Streeck H. Pušnik J, et al. NPJ Vaccines. 2024 Nov 21;9(1):231. doi: 10.1038/s41541-024-01023-7. NPJ Vaccines. 2024. PMID: 39572559 Free PMC article.

9

MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates.

Peralta-Álvarez MP, Downward K, White A, Redondo Azema H, Sibley L, Sarfas C, Morrison A, Dennis M, Diaz-Santana D, Harris SA, Li S, Puentes E, Aguilo N, Martin C, Sharpe S, McShane H, Tanner R. Peralta-Álvarez MP, et al. NPJ Vaccines. 2024 Nov 20;9(1):230. doi: 10.1038/s41541-024-01009-5. NPJ Vaccines. 2024. PMID: 39567530 Free PMC article.

10

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine.

Modjarrad K, Che Y, Chen W, Wu H, Cadima CI, Muik A, Maddur MS, Tompkins KR, Martinez LT, Cai H, Ramos M, Mensah S, Cumbia B, Falcao L, McKeen AP, Chang JS, Fennell KF, Huynh KW, McLellan TJ, Sahasrabudhe PV, Chen W, Cerswell M, Garcia MA, Li S, Sharma R, Li W, Dizon KP, Duarte S, Gillett F, Smith R, Illenberger DM, Efferen KS, Vogel AB, Anderson AS, Şahin U, Swanson KA. Modjarrad K, et al. NPJ Vaccines. 2024 Nov 20;9(1):229. doi: 10.1038/s41541-024-01013-9. NPJ Vaccines. 2024. PMID: 39567521 Free PMC article.

11

Boosting neuraminidase immunity in the presence of hemagglutinin with the next generation of influenza vaccines.

Cortés G, Ustyugova I, Farrell T, McDaniel C, Britain C, Romano C, N'Diaye S, Zheng L, Ferdous M, Iampietro J, Pougatcheva S, La Rue L, Han L, Ma F, Stegalkina S, Ray S, Zhang J, Barro M. Cortés G, et al. NPJ Vaccines. 2024 Nov 19;9(1):228. doi: 10.1038/s41541-024-01011-x. NPJ Vaccines. 2024. PMID: 39562599 Free PMC article.

12

Impact of rotavirus vaccination in Malawi from 2012 to 2022 compared to model predictions.

Pitzer VE, Ndeketa L, Asare EO, Hungerford D, Lopman BA, Jere KC, Cunliffe NA. Pitzer VE, et al. NPJ Vaccines. 2024 Nov 19;9(1):227. doi: 10.1038/s41541-024-01008-6. NPJ Vaccines. 2024. PMID: 39562592 Free PMC article.

13

Author Correction: Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine.

Bhattacharya A, Jan L, Burlak O, Li J, Upadhyay G, Williams K, Dong J, Rohrer H, Pynn M, Simon A, Kuhlmann N, Pustylnikov S, Melo MB, Dey AK. Bhattacharya A, et al. NPJ Vaccines. 2024 Nov 18;9(1):224. doi: 10.1038/s41541-024-01020-w. NPJ Vaccines. 2024. PMID: 39557916 Free PMC article. No abstract available.

14

Probing novel epitopes on the Plasmodium falciparum circumsporozoite protein for vaccine development.

Krenger PS, Roques M, Vogt AS, Pardini A, Rothen DA, Balke I, Schnider ST, Mohsen MO, Heussler VT, Zeltins A, Bachmann MF. Krenger PS, et al. NPJ Vaccines. 2024 Nov 18;9(1):225. doi: 10.1038/s41541-024-01006-8. NPJ Vaccines. 2024. PMID: 39557901 Free PMC article.

15

NHBA antibodies elicited by 4CMenB vaccination are key for serum bactericidal activity against Neisseria gonorrhoeae.

Tzeng YL, Sannigrahi S, Stephens DS. Tzeng YL, et al. NPJ Vaccines. 2024 Nov 18;9(1):223. doi: 10.1038/s41541-024-01018-4. NPJ Vaccines. 2024. PMID: 39557897 Free PMC article.

16

Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity.

D'Souza M, Keeshan A, Gravel CA, Langlois MA, Cooper CL. D'Souza M, et al. NPJ Vaccines. 2024 Nov 18;9(1):226. doi: 10.1038/s41541-024-01022-8. NPJ Vaccines. 2024. PMID: 39557875 Free PMC article.

17

A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs.

Carey BD, Yu S, Geiger J, Ye C, Huzella LM, Reeder RJ, Mehta M, Hirsch S, Bernbaum R, Cubitt B, Pahar B, Anthony SM, Marketon A, Bernbaum JG, Tran JP, Crozier I, Martínez-Sobrido L, Worwa G, de la Torre JC, Kuhn JH. Carey BD, et al. NPJ Vaccines. 2024 Nov 17;9(1):220. doi: 10.1038/s41541-024-01012-w. NPJ Vaccines. 2024. PMID: 39551823 Free PMC article.

18

Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach.

González-Domínguez I, Puente-Massaguer E, Abdeljawad A, Lai TY, Liu Y, Loganathan M, Francis B, Lemus N, Dolange V, Boza M, Slamanig S, Martínez-Guevara JL, Krammer F, Palese P, Sun W. González-Domínguez I, et al. NPJ Vaccines. 2024 Nov 17;9(1):222. doi: 10.1038/s41541-024-01014-8. NPJ Vaccines. 2024. PMID: 39551795 Free PMC article.

19

Phase 1 clinical trial of Hantaan and Puumala virus DNA vaccines delivered by needle-free injection.

Hooper JW, Kwilas SA, Josleyn M, Norris S, Hutter JN, Hamer M, Livezey J, Paolino K, Twomey P, Koren M, Keiser P, Moon JE, Nwaeze U, Koontz J, Ledesma-Feliciano C, Landry N, Wellington T. Hooper JW, et al. NPJ Vaccines. 2024 Nov 17;9(1):221. doi: 10.1038/s41541-024-00998-7. NPJ Vaccines. 2024. PMID: 39551791 Free PMC article.

20

Implications of the apparent extinction of B/Yamagata-lineage human influenza viruses.

Barr IG, Subbarao K. Barr IG, et al. NPJ Vaccines. 2024 Nov 16;9(1):219. doi: 10.1038/s41541-024-01010-y. NPJ Vaccines. 2024. PMID: 39550399 Free PMC article.

21

Mapping global public perspectives on mRNA vaccines and therapeutics.

Xu J, Wu Z, Wass L, Larson HJ, Lin L. Xu J, et al. NPJ Vaccines. 2024 Nov 14;9(1):218. doi: 10.1038/s41541-024-01019-3. NPJ Vaccines. 2024. PMID: 39543153 Free PMC article.

22

A highly immunogenic UVC inactivated Sabin based polio vaccine.

Tobin GJ, Tobin JK, Wiggins TJ, Bushnell RV, Kozar AV, Maale MF, MacLeod DA, Meeks HN, Daly MJ, Dollery SJ. Tobin GJ, et al. NPJ Vaccines. 2024 Nov 14;9(1):217. doi: 10.1038/s41541-024-00995-w. NPJ Vaccines. 2024. PMID: 39543143 Free PMC article.

23

A multi-epitope subunit vaccine providing broad cross-protection against diverse serotypes of Streptococcus suis.

Liu J, Zhang Z, Pu W, Pan X, Li P, Bai Q, Liang S, Li C, Yu Y, Yao H, Ma J. Liu J, et al. NPJ Vaccines. 2024 Nov 14;9(1):216. doi: 10.1038/s41541-024-01015-7. NPJ Vaccines. 2024. PMID: 39543108 Free PMC article.

24

Irradiated whole cell Chlamydia vaccine confers significant protection in a murine genital tract challenge model.

Broder KC, Matrosova VY, Tkavc R, Gaidamakova EK, Ho LTVT, Macintyre AN, Soc A, Diallo A, Darnell SC, Bash S, Daly MJ, Jerse AE, Liechti GW. Broder KC, et al. NPJ Vaccines. 2024 Nov 11;9(1):207. doi: 10.1038/s41541-024-00968-z. NPJ Vaccines. 2024. PMID: 39528548 Free PMC article.

25

Improving precision of vaccine efficacy evaluation using immune correlate data in time-to-event models.

Dudášová J, Valenta Z, Sachs JR. Dudášová J, et al. NPJ Vaccines. 2024 Nov 11;9(1):214. doi: 10.1038/s41541-024-00937-6. NPJ Vaccines. 2024. PMID: 39528514 Free PMC article.

26

Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera.

Xu K, An Y, Liu X, Xie H, Li D, Yang T, Duan M, Wang Y, Zhao X, Dai L, Gao GF. Xu K, et al. NPJ Vaccines. 2024 Nov 11;9(1):215. doi: 10.1038/s41541-024-01016-6. NPJ Vaccines. 2024. PMID: 39528468 Free PMC article.

27

Assessing acute kidney injury risk after COVID vaccination and infection in a large cohort study.

Pan Y, Han Y, Zhou C, Zheng J, Zhao L, Ye X, He Y; N3C Consortium. Pan Y, et al. NPJ Vaccines. 2024 Nov 8;9(1):213. doi: 10.1038/s41541-024-00964-3. NPJ Vaccines. 2024. PMID: 39516206 Free PMC article.

28

CRISPR/Cas9 screens identify key host factors that enhance rotavirus reverse genetics efficacy and vaccine production.

Zhu Y, Sullender ME, Campbell DE, Wang L, Lee S, Kawagishi T, Hou G, Dizdarevic A, Jais PH, Baldridge MT, Ding S. Zhu Y, et al. NPJ Vaccines. 2024 Nov 6;9(1):211. doi: 10.1038/s41541-024-01007-7. NPJ Vaccines. 2024. PMID: 39505878 Free PMC article.

29

Leishmania tarentolae as a platform for the production of vaccines against viral pathogens.

Zimna M, Krol E. Zimna M, et al. NPJ Vaccines. 2024 Nov 6;9(1):212. doi: 10.1038/s41541-024-01005-9. NPJ Vaccines. 2024. PMID: 39505865 Free PMC article. Review.

30

Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial.

Chew CK, Wang R, Bavanandan S, Zainudin N, Zhao X, Ahmed S, Nair D, Hou L, Yahya R, Ch'ng SS, Pang LH, Abdul Aziz A, Huang H, Rajasuriar R, Wu S, Zhang Z, Wang X, Chun GY, Mohd Norzi A, Cheah KY, Lee YL, Wan Mohamad WH, Mohd Din MR, Wan Ahmad Kamil WMR, Tan MH, Xu X, Wang L, Yan M, Liu Y, Chin VK, Teo JS, Lim TO, Zhu T, Gou J, Ng SSM. Chew CK, et al. NPJ Vaccines. 2024 Oct 31;9(1):209. doi: 10.1038/s41541-024-01003-x. NPJ Vaccines. 2024. PMID: 39482336 Free PMC article.

31

Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization.

Hong-Nguyen YK, Toerner J, Lee L, Allende MC, Kaslow DC. Hong-Nguyen YK, et al. NPJ Vaccines. 2024 Oct 31;9(1):210. doi: 10.1038/s41541-024-01002-y. NPJ Vaccines. 2024. PMID: 39482296 Free PMC article. Review.

32

Immune correlates of protection as a game changer in tuberculosis vaccine development.

Wang J, Fan XY, Hu Z. Wang J, et al. NPJ Vaccines. 2024 Oct 30;9(1):208. doi: 10.1038/s41541-024-01004-w. NPJ Vaccines. 2024. PMID: 39478007 Free PMC article. Review.

33

High protection and transmission-blocking immunity elicited by single-cycle SARS-CoV-2 vaccine in hamsters.

Lett MJ, Otte F, Hauser D, Schön J, Kipfer ET, Hoffmann D, Halwe NJ, Breithaupt A, Ulrich L, Britzke T, Kochmann J, Corleis B, Zhang Y, Urda L, Cmiljanovic V, Lang C, Beer M, Mittelholzer C, Klimkait T. Lett MJ, et al. NPJ Vaccines. 2024 Oct 30;9(1):206. doi: 10.1038/s41541-024-00992-z. NPJ Vaccines. 2024. PMID: 39472701 Free PMC article.

34

Evaluation of adenoviral vector Ad19a encoding RSV-F as novel vaccine against respiratory syncytial virus.

Fuchs J, Hübner J, Schmidt A, Irrgang P, Maier C, Vieira Antão A, Oltmanns F, Thirion C, Lapuente D, Tenbusch M. Fuchs J, et al. NPJ Vaccines. 2024 Oct 29;9(1):205. doi: 10.1038/s41541-024-01001-z. NPJ Vaccines. 2024. PMID: 39472590 Free PMC article.

35

Reply to: mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination.

Li JX, Wang YH, Bair H, Hsu SB, Chen C, Wei JC, Lin CJ. Li JX, et al. NPJ Vaccines. 2024 Oct 28;9(1):203. doi: 10.1038/s41541-024-00984-z. NPJ Vaccines. 2024. PMID: 39468071 Free PMC article.

36

mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination.

Shaia JK, Shukla P, Jampol L, Singh RP. Shaia JK, et al. NPJ Vaccines. 2024 Oct 28;9(1):202. doi: 10.1038/s41541-024-00983-0. NPJ Vaccines. 2024. PMID: 39468063 Free PMC article.

37

Proteomic approach to identify host cell attachment proteins provides protective Pseudomonas aeruginosa vaccine antigen FtsZ.

Jurado-Martín I, Tomás-Cortázar J, Hou Y, Sainz-Mejías M, Mysior MM, Sadonès O, Huebner J, Romero-Saavedra F, Simpson JC, Baugh JA, McClean S. Jurado-Martín I, et al. NPJ Vaccines. 2024 Oct 28;9(1):204. doi: 10.1038/s41541-024-00994-x. NPJ Vaccines. 2024. PMID: 39468053 Free PMC article.

38

Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.

Moreno A, Manning K, Azeem MI, Nooka AK, Ellis M, Manalo RJ, Switchenko JM, Wali B, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Dhodapkar KM, Dhodapkar MV, Suthar MS. Moreno A, et al. NPJ Vaccines. 2024 Oct 27;9(1):201. doi: 10.1038/s41541-024-00999-6. NPJ Vaccines. 2024. PMID: 39465249 Free PMC article.

39

Effect of RTS,S/AS01_E vaccine booster dose on cellular immune responses in African infants and children.

Mitchell RA, Macià D, Jairoce C, Mpina M, Naidu A, Chopo-Pizarro A, Vázquez-Santiago M, Campo JJ, Aide P, Aguilar R, Daubenberger C, Dobaño C, Moncunill G. Mitchell RA, et al. NPJ Vaccines. 2024 Oct 25;9(1):200. doi: 10.1038/s41541-024-00977-y. NPJ Vaccines. 2024. PMID: 39455625 Free PMC article.

40

Interferon as an immunoadjuvant to enhance antibodies following influenza B infection and vaccination in ferrets.

Rowe T, Fletcher A, Svoboda P, Pohl J, Hatta Y, Jasso G, Wentworth DE, Ross TM. Rowe T, et al. NPJ Vaccines. 2024 Oct 24;9(1):199. doi: 10.1038/s41541-024-00973-2. NPJ Vaccines. 2024. PMID: 39448628 Free PMC article.

41

Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates.

Thiam LG, McHugh K, Ba A, Li R, Guo Y, Pouye MN, Cisse A, Pipini D, Diallo F, Sene SD, Patel SD, Thiam A, Sadio BD, Mbengue A, Vigan-Womas I, Sheng Z, Shapiro L, Draper SJ, Bei AK. Thiam LG, et al. NPJ Vaccines. 2024 Oct 24;9(1):198. doi: 10.1038/s41541-024-00986-x. NPJ Vaccines. 2024. PMID: 39448626 Free PMC article.

42

Toxoplasma WH3 Δrop18 acts as a live attenuated vaccine against acute and chronic toxoplasmosis.

Wang C, Fu S, Yu X, Zhou H, Zhang F, Song L, Zhao J, Yang Y, Du J, Luo Q, Shen J, Yu L. Wang C, et al. NPJ Vaccines. 2024 Oct 23;9(1):197. doi: 10.1038/s41541-024-00996-9. NPJ Vaccines. 2024. PMID: 39443531 Free PMC article.

43

A comprehensive investigation of Glycoprotein-based nucleic acid vaccines for Hantaan Virus.

Zhang J, Zhang J, Wang Y, Sun Y, Wang Y, Wang Y, Yang D, Qiao X, Liu X, Ding J, Zhang X, Zhang W, Wang Z, Hu C, Han C, Liu T, Yang S, Sun Y, Cheng L, Jiang D, Yang K. Zhang J, et al. NPJ Vaccines. 2024 Oct 23;9(1):196. doi: 10.1038/s41541-024-00991-0. NPJ Vaccines. 2024. PMID: 39443512 Free PMC article.

44

Broad cross neutralizing antibodies against sarbecoviruses generated by SARS-CoV-2 infection and vaccination in humans.

Hu Y, Wu Q, Chang F, Yang J, Zhang X, Wang Q, Chen J, Teng S, Liu Y, Zheng X, Wang Y, Lu R, Pan D, Liu Z, Liu F, Xie T, Wu C, Tang Y, Tang F, Qian J, Chen H, Liu W, Li YP, Qu X. Hu Y, et al. NPJ Vaccines. 2024 Oct 22;9(1):195. doi: 10.1038/s41541-024-00997-8. NPJ Vaccines. 2024. PMID: 39438493 Free PMC article.

45

Adenovirus type 5-expressing Gn induces better protective immunity than Gc against SFTSV infection in mice.

Qian H, Tian L, Liu W, Liu L, Li M, Zhao Z, Lei X, Zheng W, Zhao Z, Zheng X. Qian H, et al. NPJ Vaccines. 2024 Oct 19;9(1):194. doi: 10.1038/s41541-024-00993-y. NPJ Vaccines. 2024. PMID: 39426985 Free PMC article.

46

A Plasmodium late liver stage arresting GAP provides superior protection in mice.

Mishra A, Paul P, Srivastava M, Mishra S. Mishra A, et al. NPJ Vaccines. 2024 Oct 18;9(1):193. doi: 10.1038/s41541-024-00975-0. NPJ Vaccines. 2024. PMID: 39424860 Free PMC article.

47

Long term T cell response and safety of a tetravalent dengue vaccine in healthy children.

Mandaric S, Friberg H, Saez-Llorens X, Borja-Tabora C, Biswal S, Escudero I, Faccin A, Gottardo R, Brose M, Roubinis N, Fladager D, DeAntonio R, Dimero JAL, Montenegro N, Folschweiller N, Currier JR, Sharma M, Tricou V. Mandaric S, et al. NPJ Vaccines. 2024 Oct 17;9(1):192. doi: 10.1038/s41541-024-00967-0. NPJ Vaccines. 2024. PMID: 39420169 Free PMC article.

48

A multiantigenic Orf virus-based vaccine efficiently protects hamsters and nonhuman primates against SARS-CoV-2.

Reguzova A, Müller M, Pagallies F, Burri D, Salomon F, Rziha HJ, Bittner-Schrader Z, Verstrepen BE, Böszörményi KP, Verschoor EJ, Gerhauser I, Elbers K, Esen M, Manenti A, Monti M, Rammensee HG, Derouazi M, Löffler MW, Amann R. Reguzova A, et al. NPJ Vaccines. 2024 Oct 16;9(1):191. doi: 10.1038/s41541-024-00981-2. NPJ Vaccines. 2024. PMID: 39414789 Free PMC article.

49

A novel outer membrane vesicle adjuvant improves vaccine protection against Bordetella pertussis.

Galeas-Pena M, Hirsch A, Kuang E, Hoffmann J, Gellings P, Brown JB, Limbert VM, Callahan CL, McLachlan JB, Morici LA. Galeas-Pena M, et al. NPJ Vaccines. 2024 Oct 16;9(1):190. doi: 10.1038/s41541-024-00990-1. NPJ Vaccines. 2024. PMID: 39406780 Free PMC article.

50

An mRNA vaccine candidate encoding H5HA clade 2.3.4.4b protects mice from clade 2.3.2.1a virus infection.

Chiba S, Kiso M, Yamada S, Someya K, Onodera Y, Yamaguchi A, Matsunaga S, Uraki R, Iwatsuki-Horimoto K, Yamayoshi S, Takeshita F, Kawaoka Y. Chiba S, et al. NPJ Vaccines. 2024 Oct 14;9(1):189. doi: 10.1038/s41541-024-00988-9. NPJ Vaccines. 2024. PMID: 39402112 Free PMC article.

51

Aerosol immunization with influenza matrix, nucleoprotein, or both prevents lung disease in pig.

Vatzia E, Paudyal B, Dema B, Carr BV, Sedaghat-Rostami E, Gubbins S, Sharma B, Moorhouse E, Morris S, Ulaszewska M, MacLoughlin R, Salguero FJ, Gilbert SC, Tchilian E. Vatzia E, et al. NPJ Vaccines. 2024 Oct 13;9(1):188. doi: 10.1038/s41541-024-00989-8. NPJ Vaccines. 2024. PMID: 39397062 Free PMC article.

52

Recombinant RSV G protein vaccine induces enhanced respiratory disease via IL-13 and mucin overproduction.

Kawahara E, Senpuku K, Kawaguchi Y, Yamamoto S, Yasuda K, Kuroda E, Ouji-Sageshima N, Ito T, Hirai T, Shibata T, Yoshioka Y. Kawahara E, et al. NPJ Vaccines. 2024 Oct 12;9(1):187. doi: 10.1038/s41541-024-00987-w. NPJ Vaccines. 2024. PMID: 39394212 Free PMC article.

53

Filovirus vaccines as a response paradigm for emerging infectious diseases.

Marzi A, Feldmann H. Marzi A, et al. NPJ Vaccines. 2024 Oct 11;9(1):186. doi: 10.1038/s41541-024-00985-y. NPJ Vaccines. 2024. PMID: 39394249 Free PMC article. Review.

54

Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections.

Alirezaylavasani A, Skeie LG, Egner IM, Chopra A, Dahl TB, Prebensen C, Vaage JT, Halvorsen B, Lund-Johansen F, Tonby K, Reikvam DH, Stiksrud B, Holter JC, Dyrhol-Riise AM, Munthe LA, Kared H. Alirezaylavasani A, et al. NPJ Vaccines. 2024 Oct 9;9(1):185. doi: 10.1038/s41541-024-00972-3. NPJ Vaccines. 2024. PMID: 39384763 Free PMC article.

55

Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens.

Miranda MC, Kepl E, Navarro MJ, Chen C, Johnson M, Sprouse KR, Stewart C, Palser A, Valdez A, Pettie D, Sydeman C, Ogohara C, Kraft JC, Pham M, Murphy M, Wrenn S, Fiala B, Ravichandran R, Ellis D, Carter L, Corti D, Kellam P, Lee K, Walls AC, Veesler D, King NP. Miranda MC, et al. NPJ Vaccines. 2024 Oct 8;9(1):184. doi: 10.1038/s41541-024-00982-1. NPJ Vaccines. 2024. PMID: 39379400 Free PMC article.

56

Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines.

Hauguel T, Sharma A, Mastrocola E, Lowry S, Maddur MS, Hu CH, Rajput S, Vitsky A, Choudhary S, Manickam B, De Souza I, Chervona Y, Moreno RM, Abdon C, Falcao L, Tompkins K, Illenberger D, Smith R, Meng F, Shi S, Efferen KS, Markiewicz V, Umemoto C, Hu J, Chen W, Scully I, Rohde CM, Anderson AS, Suphaphiphat Allen P. Hauguel T, et al. NPJ Vaccines. 2024 Oct 7;9(1):183. doi: 10.1038/s41541-024-00980-3. NPJ Vaccines. 2024. PMID: 39375384 Free PMC article.

57

DNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma.

Neeli P, Maza PAMA, Chai D, Zhao D, Hoi XP, Chan KS, Young KH, Li Y. Neeli P, et al. NPJ Vaccines. 2024 Oct 1;9(1):180. doi: 10.1038/s41541-024-00979-w. NPJ Vaccines. 2024. PMID: 39353958 Free PMC article.

58

Interventions for the control of Crimean-Congo hemorrhagic fever and tick vectors.

de la Fuente J, Ghosh S, Lempereur L, Garrison A, Sprong H, Lopez-Camacho C, Maritz-Olivier C, Contreras M, Moraga-Fernández A, Bente DA. de la Fuente J, et al. NPJ Vaccines. 2024 Oct 1;9(1):181. doi: 10.1038/s41541-024-00970-5. NPJ Vaccines. 2024. PMID: 39353956 Free PMC article. Review.

59

Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection.

Atochina-Vasserman EN, Lindesmith LC, Mirabelli C, Ona NA, Reagan EK, Brewer-Jensen PD, Mercado-Lopez X, Shahnawaz H, Meshanni JA, Baboo I, Mallory ML, Zweigart MR, May SR, Mui BL, Tam YK, Wobus CE, Baric RS, Weissman D. Atochina-Vasserman EN, et al. NPJ Vaccines. 2024 Oct 1;9(1):182. doi: 10.1038/s41541-024-00976-z. NPJ Vaccines. 2024. PMID: 39353926 Free PMC article.

60

Mosaic HIV-1 vaccine and SHIV challenge strain V2 loop sequence identity and protection in primates.

Vanshylla K, Tolboom J, Stephenson KE, Feddes-de Boer K, Verwilligen A, Rosendahl Huber SK, Rutten L, Schuitemaker H, Zahn RC, Barouch DH, Wegmann F. Vanshylla K, et al. NPJ Vaccines. 2024 Sep 30;9(1):179. doi: 10.1038/s41541-024-00974-1. NPJ Vaccines. 2024. PMID: 39349488 Free PMC article.

61

Effectiveness of influenza vaccines in preventing acute cardiovascular events within 1 year in Beijing, China.

Ma Y, Lu F, Suo L, Li W, Qian J, Wang T, Lv M, Wu J, Yang W, Guo M, Li J, Feng L. Ma Y, et al. NPJ Vaccines. 2024 Sep 28;9(1):177. doi: 10.1038/s41541-024-00969-y. NPJ Vaccines. 2024. PMID: 39341846 Free PMC article.

62

Rationally designed Mycoplasma gallisepticum vaccine using a recombinant subunit approach.

Miller JM, Ozyck RG, Pagano PL, Hernandez EF, Davis ME, Karam AQ, Malek JB, Mara AB, Tulman ER, Szczepanek SM, Geary SJ. Miller JM, et al. NPJ Vaccines. 2024 Sep 28;9(1):178. doi: 10.1038/s41541-024-00978-x. NPJ Vaccines. 2024. PMID: 39341840 Free PMC article.

63

Development of T follicular helper cell-independent nanoparticle vaccines for SARS-CoV-2 or HIV-1 by targeting ICOSL.

Zhang Y, Chen A, Li D, Yuan Q, Zhu A, Deng J, Wang Y, Liu J, Liang C, Li W, Fang Q, Xie J, Zhang X, Zhang X, Zhang Y, Chen R, Pan T, Zhang H, He X. Zhang Y, et al. NPJ Vaccines. 2024 Sep 28;9(1):176. doi: 10.1038/s41541-024-00971-4. NPJ Vaccines. 2024. PMID: 39341822 Free PMC article.

64

Author Correction: A randomized study to evaluate the safety and immunogenicity of a pentavalent meningococcal vaccine.

Kim Y, Bae S, Yu KS, Lee S, Lee C, Kim J, Her H, Oh J. Kim Y, et al. NPJ Vaccines. 2024 Sep 19;9(1):175. doi: 10.1038/s41541-024-00965-2. NPJ Vaccines. 2024. PMID: 39300100 Free PMC article. No abstract available.

65

Evaluation of effectiveness and safety of Subolesin anti-tick vaccine in Ugandan multi-site field trial.

Kabi F, Contreras M, Semakula J, Sánchez-Sánchez M, Muñoz-Hernández C, Mugerwa S, Kasaija P, Kirunda H, de la Fuente G, Fernández-Melgar R, Rafael M, Fernández de Mera IG, Matovu M, Kyakuwa I, Dhikusooka M, Nsereko G, Boma P, Bugeza J, Moses M, Namukasa A, Obonyo P, Ssekabunga N, Adyero OE, Rutaisire J, Gortazar C, de la Fuente J. Kabi F, et al. NPJ Vaccines. 2024 Sep 18;9(1):174. doi: 10.1038/s41541-024-00966-1. NPJ Vaccines. 2024. PMID: 39294184 Free PMC article.

66

Low-frequency CD8⁺ T cells induced by SIGN-R1⁺ macrophage-targeted vaccine confer SARS-CoV-2 clearance in mice.

Muraoka D, Moi ML, Muto O, Nakatsukasa T, Deng S, Takashima C, Yamaguchi R, Sawada SI, Hayakawa H, Nguyen TTN, Haseda Y, Soga T, Matsushita H, Ikeda H, Akiyoshi K, Harada N. Muraoka D, et al. NPJ Vaccines. 2024 Sep 18;9(1):173. doi: 10.1038/s41541-024-00961-6. NPJ Vaccines. 2024. PMID: 39294173 Free PMC article.

67

Author Correction: The direct effect of SARS-CoV-2 virus vaccination on human ovarian granulosa cells explains menstrual irregularities.

Bar-Joseph H, Raz Y, Eldar-Boock A, Michaan N, Angel Y, Saiag E, Nemerovsky L, Ben-Ami I, Shalgi R, Grisaru D. Bar-Joseph H, et al. NPJ Vaccines. 2024 Sep 18;9(1):172. doi: 10.1038/s41541-024-00956-3. NPJ Vaccines. 2024. PMID: 39294169 Free PMC article. No abstract available.

68

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.

Casazza JP, Hofstetter AR, Costner PJM, Holman LA, Hendel CS, Widge AT, Wu RL, Whalen WR, Cunningham J, Arthur A, Wang X, Ola A, Saunders J, Mendoza F, Novik L, Burgos Florez MC, Ortega-Villa AM, Apte PJ, Strom L, Wang L, Imam M, Basappa M, Naisan M, Castro M, Trost JF, Narpala SR, Vanderven HA, Yamshchikov GV, Berkowitz NM, Gordon IJ, Plummer SH, Wycuff DL, Vazquez S, Gillespie RA, Creanga A, Adams WC, Carlton K, Gall JG, McDermott AB, Serebryannyy LA, Houser KV, Koup RA, Graham BS, Ledgerwood JE, Mascola JR, Pierson TC, Andrews SF, Kanekiyo M, Dropulic LK; VRC 323 study team. Casazza JP, et al. NPJ Vaccines. 2024 Sep 17;9(1):171. doi: 10.1038/s41541-024-00959-0. NPJ Vaccines. 2024. PMID: 39289377 Free PMC article.

69

Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity.

Rathnasinghe R, Chang LA, Pearl R, Jangra S, Aspelund A, Hoag A, Yildiz S, Mena I, Sun W, Loganathan M, Crossland NA, Gertje HP, Tseng AE, Aslam S, Albrecht RA, Palese P, Krammer F, Schotsaert M, Muster T, García-Sastre A. Rathnasinghe R, et al. NPJ Vaccines. 2024 Sep 16;9(1):169. doi: 10.1038/s41541-024-00952-7. NPJ Vaccines. 2024. PMID: 39300090 Free PMC article.

70

CircRNA based multivalent neuraminidase vaccine induces broad protection against influenza viruses in mice.

Yue X, Zhong C, Cao R, Liu S, Qin Z, Liu L, Zhai Y, Luo W, Lian Y, Zhang M, Lu H, Wang Y, Xu M, Liu S, Lv K, Sun Y, Zhu X, Mai H, Liao J, Yang J, Deng L, Liu Y, Sun C, Zheng KW, Shu Y, Chen YQ. Yue X, et al. NPJ Vaccines. 2024 Sep 16;9(1):170. doi: 10.1038/s41541-024-00963-4. NPJ Vaccines. 2024. PMID: 39285168 Free PMC article.

71

COVID-19 vaccine refusal is driven by deliberate ignorance and cognitive distortions.

Fuławka K, Hertwig R, Pachur T. Fuławka K, et al. NPJ Vaccines. 2024 Sep 14;9(1):167. doi: 10.1038/s41541-024-00951-8. NPJ Vaccines. 2024. PMID: 39271718 Free PMC article.

72

Understanding the rationales and information environments for early, late, and nonadopters of the COVID-19 vaccine.

Singh L, Bao L, Bode L, Budak C, Pasek J, Raghunathan T, Traugott M, Wang Y, Wycoff N. Singh L, et al. NPJ Vaccines. 2024 Sep 14;9(1):168. doi: 10.1038/s41541-024-00962-5. NPJ Vaccines. 2024. PMID: 39271667 Free PMC article.

73

Risk benefit analysis to evaluate risk of thromboembolic events after mRNA COVID-19 vaccination and COVID-19.

Tran HNQ, Risk M, Nair GB, Zhao L. Tran HNQ, et al. NPJ Vaccines. 2024 Sep 13;9(1):166. doi: 10.1038/s41541-024-00960-7. NPJ Vaccines. 2024. PMID: 39271677 Free PMC article.

74

WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58.

Kemp TJ, Panicker G, Eklund C, Nie J, Wang Y, Beddows S, Rigsby P, Huang W, Dillner J, Unger ER, Pinto LA, Wilkinson DE; collaborative study participants. Kemp TJ, et al. NPJ Vaccines. 2024 Sep 10;9(1):165. doi: 10.1038/s41541-024-00949-2. NPJ Vaccines. 2024. PMID: 39256440 Free PMC article.

75

Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants.

Vishwanath S, Carnell GW, Billmeier M, Ohlendorf L, Neckermann P, Asbach B, George C, Sans MS, Chan A, Olivier J, Nadesalingam A, Einhauser S, Temperton N, Cantoni D, Grove J, Jordan I, Sandig V, Tonks P, Geiger J, Dohmen C, Mummert V, Samuel AR, Plank C, Kinsley R, Wagner R, Heeney JL. Vishwanath S, et al. NPJ Vaccines. 2024 Sep 9;9(1):164. doi: 10.1038/s41541-024-00950-9. NPJ Vaccines. 2024. PMID: 39251608 Free PMC article.

76

Applying causal inference and Bayesian statistics to understanding vaccine safety signals using a simulation study.

Tay E, Dymock M, Lopez L, Glover C, Huang YA, Bakar KS, Snelling T, Marsh JA, Wu Y. Tay E, et al. NPJ Vaccines. 2024 Sep 7;9(1):163. doi: 10.1038/s41541-024-00955-4. NPJ Vaccines. 2024. PMID: 39244611 Free PMC article.

77

Progress on the research and development of plague vaccines with a call to action.

Williamson ED, Kilgore PB, Hendrix EK, Neil BH, Sha J, Chopra AK. Williamson ED, et al. NPJ Vaccines. 2024 Sep 7;9(1):162. doi: 10.1038/s41541-024-00958-1. NPJ Vaccines. 2024. PMID: 39242587 Free PMC article. Review.

78

M2e nanovaccines supplemented with recombinant hemagglutinin protect chickens against heterologous HPAI H5N1 challenge.

Calzas C, Alkie TN, Suderman M, Embury-Hyatt C, Khatri V, Le Goffic R, Berhane Y, Bourgault S, Archambault D, Chevalier C. Calzas C, et al. NPJ Vaccines. 2024 Sep 5;9(1):161. doi: 10.1038/s41541-024-00944-7. NPJ Vaccines. 2024. PMID: 39237609 Free PMC article.

79

Broad protection and respiratory immunity of dual mRNA vaccination against SARS-CoV-2 variants.

Hajnik RL, Plante JA, Reddy Bonam S, Rafael GH, Liang Y, Hazell NC, Walker J, Reyna RA, Walker DH, Alameh MG, Weissman D, Weaver SC, Plante KS, Hu H. Hajnik RL, et al. NPJ Vaccines. 2024 Sep 4;9(1):160. doi: 10.1038/s41541-024-00957-2. NPJ Vaccines. 2024. PMID: 39232020 Free PMC article.

80

Type 5 secretion system antigens as vaccines against Gram-negative bacterial infections.

Da Costa RM, Rooke JL, Wells TJ, Cunningham AF, Henderson IR. Da Costa RM, et al. NPJ Vaccines. 2024 Sep 1;9(1):159. doi: 10.1038/s41541-024-00953-6. NPJ Vaccines. 2024. PMID: 39218947 Free PMC article. Review.

81

An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection.

Zhou D, Cheng R, Yao Y, Zhang G, Li X, Wang B, Wang Y, Yu F, Yang S, Liu H, Gao G, Peng Y, Chen M, Deng Z, Zhao H. Zhou D, et al. NPJ Vaccines. 2024 Aug 31;9(1):158. doi: 10.1038/s41541-024-00954-5. NPJ Vaccines. 2024. PMID: 39217188 Free PMC article.

82

Using matrix assisted laser desorption ionisation mass spectrometry combined with machine learning for vaccine authenticity screening.

Clarke R, Bharucha T, Arman BY, Gangadharan B, Gomez Fernandez L, Mosca S, Lin Q, Van Assche K, Stokes R, Dunachie S, Deats M, Merchant HA, Caillet C, Walsby-Tickle J, Probert F, Matousek P, Newton PN, Zitzmann N, McCullagh JSO. Clarke R, et al. NPJ Vaccines. 2024 Aug 28;9(1):155. doi: 10.1038/s41541-024-00946-5. NPJ Vaccines. 2024. PMID: 39198486 Free PMC article.

83

Ad26.M.Env ZIKV vaccine protects pregnant rhesus macaques and fetuses against Zika virus infection.

Martinot AJ, Cox F, Abbink P, Hecht JL, Bronson R, Borducchi EN, Rinaldi WJ, Ferguson MJ, De La Barrera RA, Zahn R, van der Fits L, Barouch DH. Martinot AJ, et al. NPJ Vaccines. 2024 Aug 28;9(1):157. doi: 10.1038/s41541-024-00927-8. NPJ Vaccines. 2024. PMID: 39198466 Free PMC article.

84

Neutralizing and binding antibody responses to SARS-CoV-2 with hybrid immunity in pregnancy.

Li L, Matsui Y, Prahl MK, Cassidy AG, Golan Y, Jigmeddagva U, Ozarslan N, Lin CY, Buarpung S, Gonzalez VJ, Chidboy MA, Basilio E, Lynch KL, Song D, Jegatheesan P, Rai DS, Govindaswami B, Needens J, Rincon M, Myatt L, Taha TY, Montano M, Ott M, Greene WC, Gaw SL. Li L, et al. NPJ Vaccines. 2024 Aug 27;9(1):156. doi: 10.1038/s41541-024-00948-3. NPJ Vaccines. 2024. PMID: 39191763 Free PMC article.

85

Telomeric repeats in the commercial SB-1 vaccine facilitate viral integration and contribute to vaccine efficacy.

You Y, Kheimar AM, Vychodil T, Kossak L, Sabsabi MA, Conradie AM, Reddy SM, Bertzbach LD, Kaufer BB. You Y, et al. NPJ Vaccines. 2024 Aug 21;9(1):154. doi: 10.1038/s41541-024-00945-6. NPJ Vaccines. 2024. PMID: 39169010 Free PMC article.

86

A multi-targeting immunotherapy ameliorates multiple facets of Alzheimer's disease in 3xTg mice.

Feng X, Hou Y, Liu J, Yan F, Dai M, Chen M, Wang J, Li J, Liu Z, Sun D, Zhang Y, Yu X, Kong W, Wu H. Feng X, et al. NPJ Vaccines. 2024 Aug 20;9(1):153. doi: 10.1038/s41541-024-00942-9. NPJ Vaccines. 2024. PMID: 39164276 Free PMC article.

87

A broad-spectrum vaccine candidate against H5 viruses bearing different sub-clade 2.3.4.4 HA genes.

Zhang Y, Cui P, Shi J, Zeng X, Jiang Y, Chen Y, Zhang J, Wang C, Wang Y, Tian G, Chen H, Kong H, Deng G. Zhang Y, et al. NPJ Vaccines. 2024 Aug 19;9(1):152. doi: 10.1038/s41541-024-00947-4. NPJ Vaccines. 2024. PMID: 39160189 Free PMC article.

88

A rationally designed antigen elicits protective antibodies against multiple nosocomial Gram-positive pathogens.

Kramarska E, Toumi E, Squeglia F, Laverde D, Napolitano V, Frapy E, Autiero I, Sadones O, Huebner J, Skurnik D, Romero-Saavedra F, Berisio R. Kramarska E, et al. NPJ Vaccines. 2024 Aug 18;9(1):151. doi: 10.1038/s41541-024-00940-x. NPJ Vaccines. 2024. PMID: 39155280 Free PMC article.

89

Lipo-pam™ adjuvanted herpes zoster vaccine induces potent gE-specific cellular and humoral immune responses.

Jeong SK, Ham SJ, Baek SH, Jung EJ, Jo HJ, Cha HR, Lee JM, Ahn BC, Yum JS, Chun E. Jeong SK, et al. NPJ Vaccines. 2024 Aug 17;9(1):150. doi: 10.1038/s41541-024-00939-4. NPJ Vaccines. 2024. PMID: 39154056 Free PMC article.

90

Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity.

Hernandez-Franco JF, Jan IM, Elzey BD, HogenEsch H. Hernandez-Franco JF, et al. NPJ Vaccines. 2024 Aug 17;9(1):149. doi: 10.1038/s41541-024-00943-8. NPJ Vaccines. 2024. PMID: 39152131 Free PMC article.

91

Crimean Congo hemorrhagic fever virus nucleoprotein and GP38 subunit vaccine combination prevents morbidity in mice.

Karaaslan E, Sorvillo TE, Scholte FEM, O'Neal TJ, Welch SR, Davies KA, Coleman-McCray JD, Harmon JR, Ritter JM, Pegan SD, Montgomery JM, Spengler JR, Spiropoulou CF, Bergeron É. Karaaslan E, et al. NPJ Vaccines. 2024 Aug 14;9(1):148. doi: 10.1038/s41541-024-00931-y. NPJ Vaccines. 2024. PMID: 39143104 Free PMC article.

92

COVID-19 and influenza vaccine uptake among pregnant women in national cohorts of England and Wales.

Gu X, Agrawal U, Midgley W, Bedston S, Anand SN, Goudie R, Byford R, Joy M, Jamie G, Hoang U, Ordóñez-Mena JM, Robertson C, Hobbs FDR, Akbari A, Sheikh A, de Lusignan S. Gu X, et al. NPJ Vaccines. 2024 Aug 14;9(1):147. doi: 10.1038/s41541-024-00934-9. NPJ Vaccines. 2024. PMID: 39143081 Free PMC article.

93

Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study.

Gray P, Mariz FC, Eklund C, Eriksson T, Faust H, Kann H, Müller M, Paavonen J, Pimenoff VN, Sehr P, Surcel HM, Dillner J, Waterboer T, Lehtinen M. Gray P, et al. NPJ Vaccines. 2024 Aug 13;9(1):146. doi: 10.1038/s41541-024-00941-w. NPJ Vaccines. 2024. PMID: 39138224 Free PMC article.

94

Dynamic clade transitions and the influence of vaccination on the spatiotemporal circulation of SARS-CoV-2 variants.

Banho CA, de Carvalho Marques B, Sacchetto L, Lima AKS, Parra MCP, Lima ARJ, Ribeiro G, Martins AJ, Barros CRDS, Elias MC, Sampaio SC, Slavov SN, Rodrigues ES, Santos EV, Covas DT, Kashima S, Brassaloti RA, Petry B, Clemente LG, Coutinho LL, Assato PA, da Silva da Costa FA, Grotto RMT, Poleti MD, Lesbon JCC, Mattos EC, Fukumasu H, Giovanetti M, Alcantara LCJ, Souza-Neto JA, Rahal P, Araújo JP Jr, Spilki FR, Althouse BM, Vasilakis N, Nogueira ML. Banho CA, et al. NPJ Vaccines. 2024 Aug 10;9(1):145. doi: 10.1038/s41541-024-00933-w. NPJ Vaccines. 2024. PMID: 39127725 Free PMC article.

95

Antibody gene features associated with binding and functional activity in malaria vaccine-derived human mAbs.

Coelho CH, Marquez S, Nguemwo Tentokam BC, Berhe AD, Miura K, Rao VN, Long CA, Doumbo OK, Sagara I, Healy S, Kleinstein SH, Duffy PE. Coelho CH, et al. NPJ Vaccines. 2024 Aug 10;9(1):144. doi: 10.1038/s41541-024-00929-6. NPJ Vaccines. 2024. PMID: 39127706 Free PMC article.

96

Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease.

Scher G, Yankowski C, Kurup D, Josleyn NM, Wilkinson ER, Wells J, Steffens J, Lynn G, Vantongeren S, Zeng X, Twenhafel N, Cashman KA, Schnell MJ. Scher G, et al. NPJ Vaccines. 2024 Aug 9;9(1):143. doi: 10.1038/s41541-024-00930-z. NPJ Vaccines. 2024. PMID: 39122759 Free PMC article.

97

Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins.

Aregay A, Slunečko J, Korva M, Bogovic P, Resman Rus K, Knap N, Beicht J, Kubinski M, Saletti G, Avšič-Županc T, Steffen I, Strle F, Osterhaus ADME, Rimmelzwaan GF. Aregay A, et al. NPJ Vaccines. 2024 Aug 7;9(1):141. doi: 10.1038/s41541-024-00936-7. NPJ Vaccines. 2024. PMID: 39112523 Free PMC article.

98

A randomized study to evaluate the safety and immunogenicity of a pentavalent meningococcal vaccine.

Kim Y, Bae S, Yu KS, Lee S, Lee C, Kim J, Her H, Oh J. Kim Y, et al. NPJ Vaccines. 2024 Aug 7;9(1):140. doi: 10.1038/s41541-024-00935-8. NPJ Vaccines. 2024. PMID: 39112515 Free PMC article.

99

Determination of DTaP vaccine potency by multiplex immunogenicity testing using electrochemiluminescence.

Friedrichs B, Rehg S, Hanschmann KM, Öppling V, Bekeredjian-Ding I. Friedrichs B, et al. NPJ Vaccines. 2024 Aug 7;9(1):142. doi: 10.1038/s41541-024-00915-y. NPJ Vaccines. 2024. PMID: 39112508 Free PMC article.

100

Immunisation of koalas against Chlamydia pecorum results in significant protection against chlamydial disease and mortality.

Phillips S, Hanger J, Grosmaire J, Mehdi A, Jelocnik M, Wong J, Timms P. Phillips S, et al. NPJ Vaccines. 2024 Aug 6;9(1):139. doi: 10.1038/s41541-024-00938-5. NPJ Vaccines. 2024. PMID: 39107329 Free PMC article.

101

Immunogenicity and biodistribution of lipid nanoparticle formulated self-amplifying mRNA vaccines against H5 avian influenza.

Cui X, Vervaeke P, Gao Y, Opsomer L, Sun Q, Snoeck J, Devriendt B, Zhong Z, Sanders NN. Cui X, et al. NPJ Vaccines. 2024 Aug 3;9(1):138. doi: 10.1038/s41541-024-00932-x. NPJ Vaccines. 2024. PMID: 39097672 Free PMC article.

102

Esoteric beliefs and CAM impact SARS-CoV-2 immunization drivers, uptake and pediatric immunization views in Germany.

Jäckle S, Timmis JK. Jäckle S, et al. NPJ Vaccines. 2024 Aug 3;9(1):137. doi: 10.1038/s41541-024-00928-7. NPJ Vaccines. 2024. PMID: 39097580 Free PMC article.

103

Mass vaccination with reassortment-impaired live H9N2 avian influenza vaccine.

Cargnin Faccin F, Cáceres CJ, Gay LC, Seibert B, van Bentem N, Rodriguez LA, Soares Fraiha AL, Cardenas M, Geiger G, Ortiz L, Carnaccini S, Kapczynski DR, Rajao DS, Perez DR. Cargnin Faccin F, et al. NPJ Vaccines. 2024 Aug 3;9(1):136. doi: 10.1038/s41541-024-00923-y. NPJ Vaccines. 2024. PMID: 39097573 Free PMC article.

104

Duck CD40L as an adjuvant enhances systemic immune responses of avian flavivirus DNA vaccine.

Huang J, Luo G, Wang W, Lu Y, Wang M, Liu M, Zhu D, Chen S, Zhao X, Yang Q, Wu Y, Zhang S, Ou X, Tian B, Sun D, He Y, Wu Z, Cheng A, Jia R. Huang J, et al. NPJ Vaccines. 2024 Aug 1;9(1):135. doi: 10.1038/s41541-024-00926-9. NPJ Vaccines. 2024. PMID: 39085226 Free PMC article.

105

A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challenge.

Harrison JJ, Nguyen W, Morgan MS, Tang B, Habarugira G, de Malmanche H, Freney ME, Modhiran N, Watterson D, Cox AL, Yan K, Yuen NKY, Bowman DH, Kirkland PD, Bielefeldt-Ohmann H, Suhrbier A, Hall RA, Rawle DJ, Hobson-Peters J. Harrison JJ, et al. NPJ Vaccines. 2024 Jul 31;9(1):134. doi: 10.1038/s41541-024-00903-2. NPJ Vaccines. 2024. PMID: 39085247 Free PMC article.

106

Universal subunit vaccine protects against multiple SARS-CoV-2 variants and SARS-CoV.

Wang G, Verma AK, Shi J, Guan X, Meyerholz DK, Bu F, Wen W, Liu B, Li F, Perlman S, Du L. Wang G, et al. NPJ Vaccines. 2024 Jul 25;9(1):133. doi: 10.1038/s41541-024-00922-z. NPJ Vaccines. 2024. PMID: 39054338 Free PMC article.

107

A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses.

Thimmiraju SR, Adhikari R, Redd JR, Villar MJ, Lee J, Liu Z, Chen YL, Sharma S, Kaur A, Uzcategui NL, Ronca SE, Chen WH, Kimata JT, Zhan B, Strych U, Bottazzi ME, Hotez PJ, Pollet J. Thimmiraju SR, et al. NPJ Vaccines. 2024 Jul 22;9(1):132. doi: 10.1038/s41541-024-00924-x. NPJ Vaccines. 2024. PMID: 39034332 Free PMC article.

108

A scoping review of global COVID-19 vaccine hesitancy among pregnant persons.

Casubhoy I, Kretz A, Tan HL, St Clair LA, Parish M, Golding H, Bersoff-Matcha SJ, Pilgrim-Grayson C, Berhane L, Pekosz A, Mostafa HH, Cox AL, Burd I, Klein SL, Morgan R. Casubhoy I, et al. NPJ Vaccines. 2024 Jul 20;9(1):131. doi: 10.1038/s41541-024-00913-0. NPJ Vaccines. 2024. PMID: 39033194 Free PMC article.

109

Safety and efficacy assessment of an mRNA rabies vaccine in dogs, rodents, and cynomolgus macaques.

Li J, Yu P, Liu Q, Xu L, Chen Y, Li Y, Zhang F, Zhu W, Peng Y. Li J, et al. NPJ Vaccines. 2024 Jul 20;9(1):130. doi: 10.1038/s41541-024-00925-w. NPJ Vaccines. 2024. PMID: 39033177 Free PMC article.

110

Homologous but not heterologous COVID-19 vaccine booster elicits IgG4+ B-cells and enhanced Omicron subvariant binding.

Hartley GE, Fryer HA, Gill PA, Boo I, Bornheimer SJ, Hogarth PM, Drummer HE, O'Hehir RE, Edwards ESJ, van Zelm MC. Hartley GE, et al. NPJ Vaccines. 2024 Jul 17;9(1):129. doi: 10.1038/s41541-024-00919-8. NPJ Vaccines. 2024. PMID: 39013889 Free PMC article.

111

Standardized immunological assays for assessing COVID-19 vaccines by the CEPI-Centralized Laboratory Network.

Azizi A, Ogbeni D, Kamuyu G, Schwartz LM, Clark C, Spencer P, Bernasconi V. Azizi A, et al. NPJ Vaccines. 2024 Jul 16;9(1):128. doi: 10.1038/s41541-024-00921-0. NPJ Vaccines. 2024. PMID: 39013875 Free PMC article.

112

Reassortment incompetent live attenuated and replicon influenza vaccines provide improved protection against influenza in piglets.

Graaf-Rau A, Schmies K, Breithaupt A, Ciminski K, Zimmer G, Summerfield A, Sehl-Ewert J, Lillie-Jaschniski K, Helmer C, Bielenberg W, Grosse Beilage E, Schwemmle M, Beer M, Harder T. Graaf-Rau A, et al. NPJ Vaccines. 2024 Jul 13;9(1):127. doi: 10.1038/s41541-024-00916-x. NPJ Vaccines. 2024. PMID: 39003272 Free PMC article.

113

Priming antibody responses to the fusion peptide in rhesus macaques.

Cottrell CA, Pratap PP, Cirelli KM, Carnathan DG, Enemuo CA, Antanasijevic A, Ozorowski G, Sewall LM, Gao H, Allen JD, Nogal B, Silva M, Bhiman J, Pauthner M, Irvine DJ, Montefiori D, Crispin M, Burton DR, Silvestri G, Crotty S, Ward AB. Cottrell CA, et al. NPJ Vaccines. 2024 Jul 12;9(1):126. doi: 10.1038/s41541-024-00918-9. NPJ Vaccines. 2024. PMID: 38997302 Free PMC article.

114

Author Correction: Mucosal bivalent live attenuated vaccine protects against human metapneumovirus and respiratory syncytial virus in mice.

Ogonczyk-Makowska D, Brun P, Vacher C, Chupin C, Droillard C, Carbonneau J, Laurent E, Dulière V, Traversier A, Terrier O, Julien T, Galloux M, Paul S, Eléouët JF, Fouret J, Hamelin ME, Pizzorno A, Boivin G, Rosa-Calatrava M, Dubois J. Ogonczyk-Makowska D, et al. NPJ Vaccines. 2024 Jul 9;9(1):125. doi: 10.1038/s41541-024-00917-w. NPJ Vaccines. 2024. PMID: 38982077 Free PMC article. No abstract available.

115

A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.

Hanboonkunupakarn B, Mukaka M, Jittamala P, Poovorawan K, Pongsuwan P, Stockdale L, Provstgaard-Morys S, Chotivanich K, Tarning J, Hoglund RM, Chimjinda N, Ewer K, Ramos-Lopez F, Day NPJ, Dondorp AM, Hill AV, White NJ, von Seidlein L, Pukrittayakamee S. Hanboonkunupakarn B, et al. NPJ Vaccines. 2024 Jul 6;9(1):124. doi: 10.1038/s41541-024-00920-1. NPJ Vaccines. 2024. PMID: 38971837 Free PMC article.

116

A modified mycobacterial growth inhibition assay for the functional assessment of vaccine-mediated immunity.

Vergara EJ, Tran AC, Paul MJ, Harrison T, Cooper A, Reljic R. Vergara EJ, et al. NPJ Vaccines. 2024 Jul 2;9(1):123. doi: 10.1038/s41541-024-00906-z. NPJ Vaccines. 2024. PMID: 38956057 Free PMC article.

117

Author Correction: Development of an anti-tauopathy mucosal vaccine specifically targeting pathologic conformers.

Tan W, Thiruppathi J, Hong SH, Puth S, Pheng S, Mun BR, Choi WS, Lee KH, Park HS, Nguyen DT, Lee MC, Jeong K, Zheng JH, Kim Y, Lee SE, Rhee JH. Tan W, et al. NPJ Vaccines. 2024 Jun 28;9(1):121. doi: 10.1038/s41541-024-00910-3. NPJ Vaccines. 2024. PMID: 38942773 Free PMC article. No abstract available.

118

Myocarditis associated with COVID-19 vaccination.

Buoninfante A, Andeweg A, Genov G, Cavaleri M. Buoninfante A, et al. NPJ Vaccines. 2024 Jun 28;9(1):122. doi: 10.1038/s41541-024-00893-1. NPJ Vaccines. 2024. PMID: 38942751 Free PMC article. Review.

119

Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.

Bissett C, Belij-Rammerstorfer S, Ulaszewska M, Smith H, Kailath R, Morris S, Powers C, Sebastian S, Sharpe HR, Allen ER, Wang Z, Cunliffe RF, Sallah HJ, Spencer AJ, Gilbert S, Tregoning JS, Lambe T. Bissett C, et al. NPJ Vaccines. 2024 Jun 26;9(1):118. doi: 10.1038/s41541-024-00912-1. NPJ Vaccines. 2024. PMID: 38926455 Free PMC article.

120

A gH/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge.

Edwards KR, Malhi H, Schmidt K, Davis AR, Homad LJ, Warner NL, Chhan CB, Scharffenberger SC, Gaffney K, Hinkley T, Potchen NB, Wang JY, Price J, McElrath MJ, Olson J, King NP, Lund JM, Moodie Z, Erasmus JH, McGuire AT. Edwards KR, et al. NPJ Vaccines. 2024 Jun 26;9(1):120. doi: 10.1038/s41541-024-00907-y. NPJ Vaccines. 2024. PMID: 38926438 Free PMC article.

121

The direct effect of SARS-CoV-2 virus vaccination on human ovarian granulosa cells explains menstrual irregularities.

Bar-Joseph H, Raz Y, Eldar-Boock A, Michaan N, Angel Y, Saiag E, Nemerovsky L, Ben-Ami I, Shalgi R, Grisaru D. Bar-Joseph H, et al. NPJ Vaccines. 2024 Jun 26;9(1):117. doi: 10.1038/s41541-024-00911-2. NPJ Vaccines. 2024. PMID: 38926432 Free PMC article.

122

A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity.

Zhao X, Zhang Y, Trejo-Cerro O, Kaplan E, Li Z, Albertsboer F, El Hammiri N, Mariz FC, Banks L, Ottonello S, Müller M. Zhao X, et al. NPJ Vaccines. 2024 Jun 26;9(1):119. doi: 10.1038/s41541-024-00914-z. NPJ Vaccines. 2024. PMID: 38926425 Free PMC article.

123

A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment.

Bland WA, Mitra D, Owens S, McEvoy K, Hogan CH, Boccuzzi L, Kirillov V, Meyer TJ, Khairallah C, Sheridan BS, Forrest JC, Krug LT. Bland WA, et al. NPJ Vaccines. 2024 Jun 24;9(1):116. doi: 10.1038/s41541-024-00908-x. NPJ Vaccines. 2024. PMID: 38914546 Free PMC article.

124

T cell independent antibody responses with class switch and memory using peptides anchored on liposomes.

Hjálmsdóttir Á, Hasler F, Waeckerle-Men Y, Duda A, López-Deber MP, Pihlgren M, Vukicevic M, Kündig TM, Johansen P. Hjálmsdóttir Á, et al. NPJ Vaccines. 2024 Jun 22;9(1):115. doi: 10.1038/s41541-024-00902-3. NPJ Vaccines. 2024. PMID: 38909055 Free PMC article.

125

Distinct dynamics of mRNA LNPs in mice and nonhuman primates revealed by in vivo imaging.

Lemdani K, Marlin R, Mayet C, Perkov V, Pascal Q, Ripoll M, Relouzat F, Dhooge N, Bossevot L, Dereuddre-Bosquet N, Dargazanli G, Thibaut-Duprey K, Haensler J, Chapon C, Prost C, Le Grand R. Lemdani K, et al. NPJ Vaccines. 2024 Jun 20;9(1):113. doi: 10.1038/s41541-024-00900-5. NPJ Vaccines. 2024. PMID: 38902327 Free PMC article.

126

Analyzing atomic force microscopy images of virus-like particles by expectation-maximization.

McCormick RA, Ralbovsky NM, Gilbraith W, Smith JP, Booksh KS. McCormick RA, et al. NPJ Vaccines. 2024 Jun 20;9(1):112. doi: 10.1038/s41541-024-00871-7. NPJ Vaccines. 2024. PMID: 38902288 Free PMC article.

127

Calcifediol boosts efficacy of ChAdOx1 nCoV-19 vaccine by upregulating genes promoting memory T cell responses.

Saroha HS, Bhat S, Das L, Dutta P, Holick MF, Sachdeva N, Marwaha RK. Saroha HS, et al. NPJ Vaccines. 2024 Jun 20;9(1):114. doi: 10.1038/s41541-024-00909-w. NPJ Vaccines. 2024. PMID: 38902265 Free PMC article.

128

Mucosal bivalent live attenuated vaccine protects against human metapneumovirus and respiratory syncytial virus in mice.

Ogonczyk-Makowska D, Brun P, Vacher C, Chupin C, Droillard C, Carbonneau J, Laurent E, Dulière V, Traversier A, Terrier O, Julien T, Galloux M, Paul S, Eléouët JF, Fouret J, Hamelin ME, Pizzorno A, Boivin G, Rosa-Calatrava M, Dubois J. Ogonczyk-Makowska D, et al. NPJ Vaccines. 2024 Jun 19;9(1):111. doi: 10.1038/s41541-024-00899-9. NPJ Vaccines. 2024. PMID: 38898106 Free PMC article.

129

Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model.

England RN, Drapeau EM, Alameh MG, Hosseinzadeh R, Weissman D, Hensley SE. England RN, et al. NPJ Vaccines. 2024 Jun 18;9(1):110. doi: 10.1038/s41541-024-00901-4. NPJ Vaccines. 2024. PMID: 38890316 Free PMC article.

130

Immune escape of avian oncogenic Marek's disease herpesvirus and antagonistic host immune responses.

Zhu ZJ, Teng M, Liu Y, Chen FJ, Yao Y, Li EZ, Luo J. Zhu ZJ, et al. NPJ Vaccines. 2024 Jun 15;9(1):109. doi: 10.1038/s41541-024-00905-0. NPJ Vaccines. 2024. PMID: 38879650 Free PMC article. Review.

131

Development of an anti-tauopathy mucosal vaccine specifically targeting pathologic conformers.

Tan W, Thiruppathi J, Hong SH, Puth S, Pheng S, Mun BR, Choi WS, Lee KH, Park HS, Nguyen DT, Lee MC, Jeong K, Zheng JH, Kim Y, Lee SE, Rhee JH. Tan W, et al. NPJ Vaccines. 2024 Jun 15;9(1):108. doi: 10.1038/s41541-024-00904-1. NPJ Vaccines. 2024. PMID: 38879560 Free PMC article.

132

A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI.

Fierro CA, Sarnecki M, Spiessens B, Go O, Day TA, Davies TA, van den Dobbelsteen G, Poolman J, Abbanat D, Haazen W. Fierro CA, et al. NPJ Vaccines. 2024 Jun 14;9(1):106. doi: 10.1038/s41541-024-00885-1. NPJ Vaccines. 2024. PMID: 38877036 Free PMC article.

133

Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland.

Macdonald C, Palmateer N, McAuley A, Lindsay L, Hasan T, Hameed SS, Hall E, Jeffrey K, Grange Z, Gousias P, Mavin S, Jarvis L, Cameron JC, Daines L, Tibble H, Simpson CR, McCowan C, Katikireddi SV, Rudan I, Fagbamigbe AF, Ritchie L, Swallow B, Moss P, Robertson C, Sheikh A, Murray J. Macdonald C, et al. NPJ Vaccines. 2024 Jun 14;9(1):107. doi: 10.1038/s41541-024-00898-w. NPJ Vaccines. 2024. PMID: 38877008 Free PMC article.

134

Genomic tailoring of autogenous poultry vaccines to reduce Campylobacter from farm to fork.

Calland JK, Pesonen ME, Mehat J, Pascoe B, Haydon DJ, Lourenco J, Lukasiewicz B, Mourkas E, Hitchings MD, La Ragione RM, Hammond P, Wallis TS, Corander J, Sheppard SK. Calland JK, et al. NPJ Vaccines. 2024 Jun 12;9(1):105. doi: 10.1038/s41541-024-00879-z. NPJ Vaccines. 2024. PMID: 38866805 Free PMC article.

135

Multivalent mRNA-DTP vaccines are immunogenic and provide protection from Bordetella pertussis challenge in mice.

Wolf MA, O'Hara JM, Bitzer GJ, Narayanan E, Boehm DT, Bevere JR, DeJong MA, Hall JM, Wong TY, Falcone S, Deal CE, Richards A, Green S, Nguyen B, King E, Ogega C, Russo L, Sen-Kilic E, Plante O, Himansu S, Barbier M, Carfi A, Damron FH. Wolf MA, et al. NPJ Vaccines. 2024 Jun 10;9(1):103. doi: 10.1038/s41541-024-00890-4. NPJ Vaccines. 2024. PMID: 38858423 Free PMC article.

136

Safety and efficacy of C. muridarum vaccines adjuvanted with CpG-1826 and four concentrations of Montanide-ISA-720-VG.

Slepenkin A, Pal S, Rasley A, Coleman MA, de la Maza LM. Slepenkin A, et al. NPJ Vaccines. 2024 Jun 10;9(1):104. doi: 10.1038/s41541-024-00880-6. NPJ Vaccines. 2024. PMID: 38858418 Free PMC article.

137

T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector.

Fert I, Douguet L, Vesin B, Moncoq F, Noirat A, Authié P, Ciret S, Le Chevalier F, Blanc C, Vitrenko Y, Charneau P, Majlessi L, Anna F. Fert I, et al. NPJ Vaccines. 2024 Jun 10;9(1):102. doi: 10.1038/s41541-024-00894-0. NPJ Vaccines. 2024. PMID: 38858404 Free PMC article.

138

Differential long-term bivalent HPV vaccine cross-protection by variants in the Costa Rica HPV vaccine trial.

Shing JZ, Porras C, Pinheiro M, Herrero R, Hildesheim A, Liu D, Gail MH, Romero B, Schiller JT, Zúñiga M, Mishra S, Burdette L, Jones K, Schussler J, Ocampo R, Fang J, Liu Z, Lowy DR, Tsang SH, Rodríguez AC, Schiffman M, Haas CB, Carvajal LJ, Brown JR, Kreimer AR, Mirabello L; Costa Rica HPV Vaccine Trial (CVT) Group. Shing JZ, et al. NPJ Vaccines. 2024 Jun 8;9(1):101. doi: 10.1038/s41541-024-00896-y. NPJ Vaccines. 2024. PMID: 38851816 Free PMC article.

139

Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses.

Rungelrath V, Ahmed M, Hicks L, Miller SM, Ryter KT, Montgomery K, Ettenger G, Riffey A, Abdelwahab WM, Khader SA, Evans JT. Rungelrath V, et al. NPJ Vaccines. 2024 Jun 6;9(1):100. doi: 10.1038/s41541-024-00897-x. NPJ Vaccines. 2024. PMID: 38844494 Free PMC article.

140

Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines.

Gardner J, Abrams ST, Toh CH, Parker AL, Lovatt C, Nicolson PLR, Watson SP, Grice S, Hering L, Pirmohamed M, Naisbitt DJ. Gardner J, et al. NPJ Vaccines. 2024 Jun 5;9(1):99. doi: 10.1038/s41541-024-00895-z. NPJ Vaccines. 2024. PMID: 38839821 Free PMC article.

141

Long-term trial of protection provided by adenovirus-vectored vaccine expressing the PPRV H protein.

Darpel KE, Corla A, Stedman A, Bellamy F, Flannery J, Rajko-Nenow P, Powers C, Wilson S, Charleston B, Baron MD, Batten C. Darpel KE, et al. NPJ Vaccines. 2024 Jun 3;9(1):98. doi: 10.1038/s41541-024-00892-2. NPJ Vaccines. 2024. PMID: 38830899 Free PMC article.

142

Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection.

Lopez CE, Zacharias ZR, Ross KA, Narasimhan B, Waldschmidt TJ, Legge KL. Lopez CE, et al. NPJ Vaccines. 2024 May 31;9(1):96. doi: 10.1038/s41541-024-00883-3. NPJ Vaccines. 2024. PMID: 38822003 Free PMC article.

143

Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge.

Pascha MN, Ballegeer M, Roelofs MC, Meuris L, Albulescu IC, van Kuppeveld FJM, Hurdiss DL, Bosch BJ, Zeev-Ben-Mordehai T, Saelens X, de Haan CAM. Pascha MN, et al. NPJ Vaccines. 2024 May 31;9(1):97. doi: 10.1038/s41541-024-00891-3. NPJ Vaccines. 2024. PMID: 38821988 Free PMC article.

144

Neoantigen-augmented iPSC cancer vaccine combined with radiotherapy promotes antitumor immunity in poorly immunogenic cancers.

Huang KC, Chen WT, Chen JY, Lee CY, Wu CH, Lai CY, Yang PC, Liang JA, Shiau AC, Chao KSC, Ke TW. Huang KC, et al. NPJ Vaccines. 2024 May 31;9(1):95. doi: 10.1038/s41541-024-00881-5. NPJ Vaccines. 2024. PMID: 38821980 Free PMC article.

145

A narrative review of norovirus epidemiology, biology, and challenges to vaccine development.

Carlson KB, Dilley A, O'Grady T, Johnson JA, Lopman B, Viscidi E. Carlson KB, et al. NPJ Vaccines. 2024 May 29;9(1):94. doi: 10.1038/s41541-024-00884-2. NPJ Vaccines. 2024. PMID: 38811605 Free PMC article. Review.

146

SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity.

Aguilar-Bretones M, den Hartog Y, van Dijk LLA, Malahe SRK, Dieterich M, Mora HT, Mueller YM, Koopmans MPG, Reinders MEJ, Baan CC, van Nierop GP, de Vries RD; RECOVAC Consortium. Aguilar-Bretones M, et al. NPJ Vaccines. 2024 May 28;9(1):93. doi: 10.1038/s41541-024-00886-0. NPJ Vaccines. 2024. PMID: 38806532 Free PMC article.

147

Sustained antigen delivery improves germinal center reaction and increases antibody responses in neonatal mice.

Lotspeich-Cole L, Parvathaneni S, Sakai J, Liu L, Takeda K, Lee RC, Akkoyunlu M. Lotspeich-Cole L, et al. NPJ Vaccines. 2024 May 25;9(1):92. doi: 10.1038/s41541-024-00875-3. NPJ Vaccines. 2024. PMID: 38796539 Free PMC article.

148

Continuing development of vaccines and monoclonal antibodies against Zika virus.

Woodson SE, Morabito KM. Woodson SE, et al. NPJ Vaccines. 2024 May 24;9(1):91. doi: 10.1038/s41541-024-00889-x. NPJ Vaccines. 2024. PMID: 38789469 Free PMC article.

149

Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges.

Warner BM, Yates JGE, Vendramelli R, Truong T, Meilleur C, Chan L, Leacy A, Pham PH, Pei Y, Susta L, Wootton SK, Kobasa D. Warner BM, et al. NPJ Vaccines. 2024 May 23;9(1):90. doi: 10.1038/s41541-024-00870-8. NPJ Vaccines. 2024. PMID: 38782986 Free PMC article.

150

Replicon particle vaccination induces non-neutralizing anti-nucleoprotein antibody-mediated control of Crimean-Congo hemorrhagic fever virus.

Sorvillo TE, Karaaslan E, Scholte FEM, Welch SR, Coleman-McCray JD, Genzer SC, Ritter JM, Hayes HM, Jain S, Pegan SD, Bergeron É, Montgomery JM, Spiropoulou CF, Spengler JR. Sorvillo TE, et al. NPJ Vaccines. 2024 May 23;9(1):88. doi: 10.1038/s41541-024-00877-1. NPJ Vaccines. 2024. PMID: 38782933 Free PMC article.

151

Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy.

Julg B, Stephenson KE, Tomaka F, Walsh SR, Sabrina Tan C, Lavreys L, Sarnecki M, Ansel JL, Kanjilal DG, Jaegle K, Speidel T, Nkolola JP, Borducchi EN, Braams E, Pattacini L, Burgess E, Ilan S, Bartsch Y, Yanosick KE, Seaman MS, Stieh DJ, van Duijn J, Willems W, Robb ML, Michael NL, Walker BD, Pau MG, Schuitemaker H, Barouch DH. Julg B, et al. NPJ Vaccines. 2024 May 23;9(1):89. doi: 10.1038/s41541-024-00876-2. NPJ Vaccines. 2024. PMID: 38782902 Free PMC article.

152

Influence of individuals' determinants including vaccine type on cellular and humoral responses to SARS-CoV-2 vaccination.

Chambers ES, Cai W, Vivaldi G, Jolliffe DA, Perdek N, Li W, Faustini SE, Gibbons JM, Pade C, Richter AG, Coussens AK, Martineau AR. Chambers ES, et al. NPJ Vaccines. 2024 May 22;9(1):87. doi: 10.1038/s41541-024-00878-0. NPJ Vaccines. 2024. PMID: 38778017 Free PMC article.

153

A replicating RNA vaccine confers protection in a rhesus macaque model of Crimean-Congo hemorrhagic fever.

Hawman DW, Leventhal SS, Meade-White K, Khandhar A, Murray J, Lovaglio J, Shaia C, Saturday G, Hinkley T, Erasmus J, Feldmann H. Hawman DW, et al. NPJ Vaccines. 2024 May 20;9(1):86. doi: 10.1038/s41541-024-00887-z. NPJ Vaccines. 2024. PMID: 38769294 Free PMC article.

154

Author Correction: Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium.

Marcos-Villar L, Perdiguero B, Anthiya S, Borrajo ML, Lou G, Franceschini L, Esteban I, Sánchez-Cordón PJ, Zamora C, Sorzano CÓS, Jordá L, Codó L, Gelpí JL, Sisteré-Oró M, Meyerhans A, Thielemans K, Martínez-Jiménez F, López-Bigas N, García F, Alonso MJ, Plana M, Esteban M, Gómez CE. Marcos-Villar L, et al. NPJ Vaccines. 2024 May 18;9(1):84. doi: 10.1038/s41541-024-00882-4. NPJ Vaccines. 2024. PMID: 38762608 Free PMC article. No abstract available.

155

Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera.

Rössler A, Netzl A, Knabl L, Wilks SH, Mühlemann B, Türeli S, Mykytyn A, von Laer D, Haagmans BL, Smith DJ, Kimpel J. Rössler A, et al. NPJ Vaccines. 2024 May 18;9(1):85. doi: 10.1038/s41541-024-00888-y. NPJ Vaccines. 2024. PMID: 38762525 Free PMC article.

156

High production of IL-12 by human dendritic cells stimulated with combinations of pattern-recognition receptor agonists.

Gilmour BC, Corthay A, Øynebråten I. Gilmour BC, et al. NPJ Vaccines. 2024 May 3;9(1):83. doi: 10.1038/s41541-024-00869-1. NPJ Vaccines. 2024. PMID: 38702320 Free PMC article.

157

Realising the potential of correlates of protection for vaccine development, licensure and use: short summary.

King DF, Groves H, Weller C, Jones I, Cramer JP, Gilbert PB, Goldblatt D, Gruber MF, Kampmann B, Maïga D, Pasetti MF, Plotkin SA, Precioso A, Wassie L, Wittke F, Kaslow DC. King DF, et al. NPJ Vaccines. 2024 Apr 29;9(1):82. doi: 10.1038/s41541-024-00872-6. NPJ Vaccines. 2024. PMID: 38684704 Free PMC article.

158

Strep A: challenges, opportunities, vaccine-based solutions, and economics.

Bloom DE, Carapetis J. Bloom DE, et al. NPJ Vaccines. 2024 Apr 19;9(1):80. doi: 10.1038/s41541-024-00863-7. NPJ Vaccines. 2024. PMID: 38641634 Free PMC article. Review.

159

Strep A: challenges, opportunities, vaccine-based solutions and economics.

Bloom DE, Titball RW, Carapetis J. Bloom DE, et al. NPJ Vaccines. 2024 Apr 19;9(1):81. doi: 10.1038/s41541-024-00864-6. NPJ Vaccines. 2024. PMID: 38641630 Free PMC article. No abstract available.

160

Author Correction: Enhanced attenuation of chikungunya vaccines expressing antiviral cytokines.

Chuong C, Cereghino C, Rai P, Bates TA, Oberer M, Weger-Lucarelli J. Chuong C, et al. NPJ Vaccines. 2024 Apr 16;9(1):79. doi: 10.1038/s41541-024-00868-2. NPJ Vaccines. 2024. PMID: 38627437 Free PMC article. No abstract available.

161

The role of correlates of protection in overcoming barriers to vaccine development and demonstrating efficacy.

King DF, Groves H, Weller C. King DF, et al. NPJ Vaccines. 2024 Apr 13;9(1):78. doi: 10.1038/s41541-024-00873-5. NPJ Vaccines. 2024. PMID: 38615121 Free PMC article. No abstract available.

162

Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies.

Hou Y, Chen M, Bian Y, Hu Y, Chuan J, Zhong L, Zhu Y, Tong R. Hou Y, et al. NPJ Vaccines. 2024 Apr 10;9(1):77. doi: 10.1038/s41541-024-00874-4. NPJ Vaccines. 2024. PMID: 38600250 Free PMC article. Review.

163

FcRn regulates antigen presentation in dendritic cells downstream of DEC205-targeted vaccines.

Macri C, Paxman M, Jenika D, Lin XP, Elahi Z, Gleeson PA, Caminschi I, Lahoud MH, Villadangos JA, Mintern JD. Macri C, et al. NPJ Vaccines. 2024 Apr 9;9(1):76. doi: 10.1038/s41541-024-00854-8. NPJ Vaccines. 2024. PMID: 38594284 Free PMC article.

164

Recovery from antibody-mediated biliary ductopenia and multiorgan inflammation after COVID-19 vaccination.

Chang A, Jeng YM, Ho CM, Lee PH. Chang A, et al. NPJ Vaccines. 2024 Apr 8;9(1):75. doi: 10.1038/s41541-024-00861-9. NPJ Vaccines. 2024. PMID: 38589436 Free PMC article.

165

Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines.

Del Moral-Sánchez I, Wee EG, Xian Y, Lee WH, Allen JD, Torrents de la Peña A, Fróes Rocha R, Ferguson J, León AN, Koekkoek S, Schermer EE, Burger JA, Kumar S, Zwolsman R, Brinkkemper M, Aartse A, Eggink D, Han J, Yuan M, Crispin M, Ozorowski G, Ward AB, Wilson IA, Hanke T, Sliepen K, Sanders RW. Del Moral-Sánchez I, et al. NPJ Vaccines. 2024 Apr 6;9(1):74. doi: 10.1038/s41541-024-00862-8. NPJ Vaccines. 2024. PMID: 38582771 Free PMC article.

166

COVID-19 vaccination induces distinct T-cell responses in pediatric solid organ transplant recipients and immunocompetent children.

Roznik K, Xue J, Stavrakis G, Johnston TS, Kalluri D, Ohsie R, Qin CX, McAteer J, Segev DL, Mogul D, Werbel WA, Karaba AH, Thompson EA, Cox AL. Roznik K, et al. NPJ Vaccines. 2024 Apr 5;9(1):73. doi: 10.1038/s41541-024-00866-4. NPJ Vaccines. 2024. PMID: 38580714 Free PMC article.

167

Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine.

Bhattacharya A, Jan L, Burlak O, Li J, Upadhyay G, Williams K, Dong J, Rohrer H, Pynn M, Simon A, Kuhlmann N, Pustylnikov S, Melo MB, Dey AK. Bhattacharya A, et al. NPJ Vaccines. 2024 Apr 4;9(1):72. doi: 10.1038/s41541-024-00865-5. NPJ Vaccines. 2024. PMID: 38575581 Free PMC article.

168

Reverse development of vaccines against antimicrobial-resistant pathogens.

Bagnoli F, Galgani I, Vadivelu VK, Phogat S. Bagnoli F, et al. NPJ Vaccines. 2024 Apr 3;9(1):71. doi: 10.1038/s41541-024-00858-4. NPJ Vaccines. 2024. PMID: 38570502 Free PMC article. Review.

169

Progress with COVID vaccine development and implementation.

Titball RW, Bernstein DI, Fanget NVJ, Hall RA, Longet S, MacAry PA, Rupp RE, van Gils M, von Messling V, Walker DH, Barrett ADT. Titball RW, et al. NPJ Vaccines. 2024 Apr 1;9(1):69. doi: 10.1038/s41541-024-00867-3. NPJ Vaccines. 2024. PMID: 38561358 Free PMC article. No abstract available.

170

Transcriptional signature of durable effector T cells elicited by a replication defective HCMV vaccine.

Ye X, Shih DJH, Ku Z, Hong J, Barrett DF, Rupp RE, Zhang N, Fu TM, Zheng WJ, An Z. Ye X, et al. NPJ Vaccines. 2024 Apr 1;9(1):70. doi: 10.1038/s41541-024-00860-w. NPJ Vaccines. 2024. PMID: 38561339 Free PMC article.

171

Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform.

Yll-Pico M, Park Y, Martinez J, Iniguez A, Kha M, Kim T, Medrano L, Nguyen VH, Kaltcheva T, Dempsey S, Chiuppesi F, Wussow F, Diamond DJ. Yll-Pico M, et al. NPJ Vaccines. 2024 Mar 30;9(1):68. doi: 10.1038/s41541-024-00859-3. NPJ Vaccines. 2024. PMID: 38555379 Free PMC article.

172

Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.

Happe M, Hofstetter AR, Wang J, Yamshchikov GV, Holman LA, Novik L, Strom L, Kiweewa F, Wakabi S, Millard M, Kelley CF, Kabbani S, Edupuganti S, Beck A, Kaltovich F, Murray T, Tsukerman S, Carr D, Ashman C, Stanley DA, Ploquin A, Bailer RT, Schwartz R, Cham F, Tindikahwa A, Hu Z, Gordon IJ, Rouphael N, Houser KV, Coates EE, Graham BS, Koup RA, Mascola JR, Sullivan NJ, Robb ML, Ake JA, Lyke KE, Mulligan MJ, Ledgerwood JE, Kibuuka H; VRC 208 and RV 422 study team. Happe M, et al. NPJ Vaccines. 2024 Mar 29;9(1):67. doi: 10.1038/s41541-024-00833-z. NPJ Vaccines. 2024. PMID: 38553525 Free PMC article.

173

Immunization-induced antigen archiving enhances local memory CD8+ T cell responses following an unrelated viral infection.

Doan TA, Forward TS, Schafer JB, Lucas ED, Fleming I, Uecker-Martin A, Ayala E, Guthmiller JJ, Hesselberth JR, Morrison TE, Tamburini BAJ. Doan TA, et al. NPJ Vaccines. 2024 Mar 21;9(1):66. doi: 10.1038/s41541-024-00856-6. NPJ Vaccines. 2024. PMID: 38514656 Free PMC article.

174

Genomic analysis of lumpy skin disease virus asian variants and evaluation of its cellular tropism.

Xie S, Cui L, Liao Z, Zhu J, Ren S, Niu K, Li H, Jiang F, Wu J, Wang J, Wu J, Song B, Wu W, Peng C. Xie S, et al. NPJ Vaccines. 2024 Mar 21;9(1):65. doi: 10.1038/s41541-024-00846-8. NPJ Vaccines. 2024. PMID: 38514651 Free PMC article.

175

An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza.

Xing M, Hu G, Wang X, Wang Y, He F, Dai W, Wang X, Niu Y, Liu J, Liu H, Zhang X, Xu J, Cai Q, Zhou D. Xing M, et al. NPJ Vaccines. 2024 Mar 21;9(1):64. doi: 10.1038/s41541-024-00857-5. NPJ Vaccines. 2024. PMID: 38509167 Free PMC article.

176

Expansion of memory Vδ2 T cells following SARS-CoV-2 vaccination revealed by temporal single-cell transcriptomics.

Terzoli S, Marzano P, Cazzetta V, Piazza R, Sandrock I, Ravens S, Tan L, Prinz I, Balin S, Calvi M, Carletti A, Cancellara A, Coianiz N, Franzese S, Frigo A, Voza A, Calcaterra F, Di Vito C, Della Bella S, Mikulak J, Mavilio D. Terzoli S, et al. NPJ Vaccines. 2024 Mar 20;9(1):63. doi: 10.1038/s41541-024-00853-9. NPJ Vaccines. 2024. PMID: 38509155 Free PMC article.

177

Design of hepadnavirus core protein-based chimeric virus-like particles carrying epitopes from respiratory syncytial virus.

Shao S, Zhang XF, Hou JW, Yang SS, Han ZB, Wu HL, Tang F, Li XY, Lei ZH, Zhao ZX, Li SX, Liu ZM, Shan P, Jin YQ, Su JG, Liang Y, Zhang J, Li QM. Shao S, et al. NPJ Vaccines. 2024 Mar 19;9(1):62. doi: 10.1038/s41541-024-00855-7. NPJ Vaccines. 2024. PMID: 38503757 Free PMC article.

178

Author Correction: Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV-workshop report.

Maciel M Jr, Amara RR, Bar KJ, Crotty S, Deeks SG, Duplessis C, Gaiha G, McElrath MJ, McMichael A, Palin A, Rutishauser R, Shapiro S, Smiley ST, D'Souza MP. Maciel M Jr, et al. NPJ Vaccines. 2024 Mar 14;9(1):61. doi: 10.1038/s41541-024-00852-w. NPJ Vaccines. 2024. PMID: 38485736 Free PMC article. No abstract available.

179

Recent progress on gene-deleted live-attenuated African swine fever virus vaccines.

Vu HLX, McVey DS. Vu HLX, et al. NPJ Vaccines. 2024 Mar 13;9(1):60. doi: 10.1038/s41541-024-00845-9. NPJ Vaccines. 2024. PMID: 38480758 Free PMC article. Review.

180

Enhanced attenuation of chikungunya vaccines expressing antiviral cytokines.

Chuong C, Cereghino C, Rai P, Bates TA, Oberer M, Weger-Lucarelli J. Chuong C, et al. NPJ Vaccines. 2024 Mar 12;9(1):59. doi: 10.1038/s41541-024-00843-x. NPJ Vaccines. 2024. PMID: 38472211 Free PMC article.

181

Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming.

deCamp AC, Corcoran MM, Fulp WJ, Willis JR, Cottrell CA, Bader DLV, Kalyuzhniy O, Leggat DJ, Cohen KW, Hyrien O, Menis S, Finak G, Ballweber-Fleming L, Srikanth A, Plyler JR, Rahaman F, Lombardo A, Philiponis V, Whaley RE, Seese A, Brand J, Ruppel AM, Hoyland W, Mahoney CR, Cagigi A, Taylor A, Brown DM, Ambrozak DR, Sincomb T, Mullen TM, Maenza J, Kolokythas O, Khati N, Bethony J, Roederer M, Diemert D, Koup RA, Laufer DS, McElrath JM, McDermott AB, Karlsson Hedestam GB, Schief WR. deCamp AC, et al. NPJ Vaccines. 2024 Mar 11;9(1):58. doi: 10.1038/s41541-024-00811-5. NPJ Vaccines. 2024. PMID: 38467663 Free PMC article.

182

Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development.

Chugh S, Bahal RK, Dhiman R, Singh R. Chugh S, et al. NPJ Vaccines. 2024 Mar 9;9(1):57. doi: 10.1038/s41541-024-00834-y. NPJ Vaccines. 2024. PMID: 38461350 Free PMC article. Review.

183

Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccine.

Conti V, Rossi O, Clarkson KA, Mancini F, Nakakana UN, Sarakinou E, Callegaro A, Ferruzzi P, Acquaviva A, Arora AK, Marchetti E, Necchi F, Frenck RW Jr, Martin LB, Kaminski RW, Podda A, Micoli F. Conti V, et al. NPJ Vaccines. 2024 Mar 8;9(1):56. doi: 10.1038/s41541-024-00822-2. NPJ Vaccines. 2024. PMID: 38459072 Free PMC article.

184

Immune response induced by standard and fractional doses of 17DD yellow fever vaccine.

Abdala-Torres T, Campi-Azevedo AC, da Silva-Pereira RA, Dos Santos LI, Henriques PM, Costa-Rocha IA, Otta DA, Peruhype-Magalhães V, Teixeira-Carvalho A, Araújo MSS, Fernandes EG, Sato HK, Fantinato FFST, Domingues CMAS, Kallás EG, Tomiyama HTI, Lemos JAC, Coelho-Dos-Reis JG, de Lima SMB, Schwarcz WD, de Souza Azevedo A, Trindade GF, Ano Bom APD, da Silva AMV, Fernandes CB, Camacho LAB, de Sousa Maia ML; Collaborative Group for Studies of Yellow Fever Vaccine; Martins-Filho OA, do Antonelli LRDV. Abdala-Torres T, et al. NPJ Vaccines. 2024 Mar 8;9(1):54. doi: 10.1038/s41541-024-00836-w. NPJ Vaccines. 2024. PMID: 38459059 Free PMC article.

185

BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice.

Kwon KW, Choi HG, Kim KS, Park SA, Kim HJ, Shin SJ. Kwon KW, et al. NPJ Vaccines. 2024 Mar 8;9(1):55. doi: 10.1038/s41541-024-00847-7. NPJ Vaccines. 2024. PMID: 38459038 Free PMC article.

186

Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium.

Marcos-Villar L, Perdiguero B, Anthiya S, Borrajo ML, Lou G, Franceschini L, Esteban I, Sánchez-Cordón PJ, Zamora C, Sorzano CÓS, Jordá L, Codó L, Gelpí JL, Sisteré-Oró M, Meyerhans A, Thielemans K, Martínez-Jiménez F, López-Bigas N, García F, Alonso MJ, Plana M, Esteban M, Gómez CE. Marcos-Villar L, et al. NPJ Vaccines. 2024 Mar 6;9(1):53. doi: 10.1038/s41541-024-00838-8. NPJ Vaccines. 2024. PMID: 38448450 Free PMC article.

187

A register and questionnaire study of long-term general health symptoms following SARS-CoV-2 vaccination in Denmark.

O'Regan E, Svalgaard IB, Sørensen AIV, Spiliopoulos L, Bager P, Nielsen NM, Hansen JV, Koch A, Meder IK, Videbech P, Ethelberg S, Hviid A. O'Regan E, et al. NPJ Vaccines. 2024 Mar 4;9(1):52. doi: 10.1038/s41541-024-00844-w. NPJ Vaccines. 2024. PMID: 38438399 Free PMC article.

188

Prospective cohort study evaluating the association between influenza vaccination and neurodegenerative diseases.

Zhao H, Zhou X, Fu K, Duan Y, Wen Q, Wang S, Zhan S. Zhao H, et al. NPJ Vaccines. 2024 Mar 2;9(1):51. doi: 10.1038/s41541-024-00841-z. NPJ Vaccines. 2024. PMID: 38431710 Free PMC article.

189

Immune persistence after different polio sequential immunization schedules in Chinese infants.

Zhao T, Li J, Huang T, Ying ZF, Che YC, Zhao ZM, Fu YT, Tao JH, Yang QH, Wei DK, Li GL, Yi L, Zhao YP, Chen HB, Wang JF, Jiang RJ, Yu L, Cai W, Yang W, Xie MX, Yin QZ, Pu J, Shi L, Hong C, Deng Y, Cai LK, Zhou J, Wen Y, Li HS, Huang W, Mo ZJ, Li CG, Li QH, Yang JS. Zhao T, et al. NPJ Vaccines. 2024 Feb 29;9(1):50. doi: 10.1038/s41541-024-00831-1. NPJ Vaccines. 2024. PMID: 38424078 Free PMC article.

190

Changes in vaccine attitudes and recommendations among US Healthcare Personnel during the COVID-19 pandemic.

Dudley MZ, Schuh HB, Forr A, Shaw J, Salmon DA. Dudley MZ, et al. NPJ Vaccines. 2024 Feb 28;9(1):49. doi: 10.1038/s41541-024-00826-y. NPJ Vaccines. 2024. PMID: 38418562 Free PMC article.

191

Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models.

Usai C, Ainsua-Enrich E, Gales VU, Pradenas E, Lorca-Oró C, Tarrés-Freixas F, Roca N, Pérez M, Ávila-Nieto C, Rodríguez de la Concepción ML, Pedreño-Lopez N, Carabelli J, Trinité B, Ballana E, Riveira-Muñoz E, Izquierdo-Useros N, Clotet B, Blanco J, Guallar V, Cantero G, Vergara-Alert J, Carrillo J, Segalés J. Usai C, et al. NPJ Vaccines. 2024 Feb 27;9(1):48. doi: 10.1038/s41541-024-00840-0. NPJ Vaccines. 2024. PMID: 38413645 Free PMC article.

192

MVA-based vaccines are protective against lethal eastern equine encephalitis virus aerosol challenge in cynomolgus macaques.

Beddingfield BJ, Plante KS, Plante JA, Weaver SC, Bose S, Krzykwa C, Chirichella N, Redmann RK, Seiler SZ, Dufour J, Blair RV, Endt K, Volkmann A, Maness NJ, Roy CJ. Beddingfield BJ, et al. NPJ Vaccines. 2024 Feb 27;9(1):47. doi: 10.1038/s41541-024-00842-y. NPJ Vaccines. 2024. PMID: 38413593 Free PMC article.

193

Impact of sex on humoral immunity with live influenza B virus vaccines in mice.

Cardenas-Garcia S, Cáceres CJ, Jain A, Geiger G, Mo JS, Gay LC, Seibert B, Jasinskas A, Nakajima R, Rajao DS, Davies DH, Perez DR. Cardenas-Garcia S, et al. NPJ Vaccines. 2024 Feb 26;9(1):45. doi: 10.1038/s41541-024-00827-x. NPJ Vaccines. 2024. PMID: 38409236 Free PMC article.

194

Conserved molecular chaperone PrsA stimulates protective immunity against group A Streptococcus.

Lai CY, Xie JX, Lai MC, Wu ZY, Lin JS, Huang YT, Chi CY, Chiang-Ni C, Walker MJ, Chang YC. Lai CY, et al. NPJ Vaccines. 2024 Feb 26;9(1):46. doi: 10.1038/s41541-024-00839-7. NPJ Vaccines. 2024. PMID: 38409165 Free PMC article.

195

Inter-epitope spacer variation within polytopic L2-based human papillomavirus antigens affects immunogenicity.

Zhang Y, Mariz FC, Sehr P, Spagnoli G, Koenig KM, Çelikyürekli S, Kreuziger T, Zhao X, Bolchi A, Ottonello S, Müller M. Zhang Y, et al. NPJ Vaccines. 2024 Feb 24;9(1):44. doi: 10.1038/s41541-024-00832-0. NPJ Vaccines. 2024. PMID: 38402256 Free PMC article.

196

Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines.

Bae KH, Shunmuganathan B, Zhang L, Lim A, Gupta R, Wang Y, Chua BL, Wang Y, Gu Y, Qian X, Tan ISL, Purushotorman K, MacAry PA, White KP, Yang YY. Bae KH, et al. NPJ Vaccines. 2024 Feb 23;9(1):43. doi: 10.1038/s41541-024-00835-x. NPJ Vaccines. 2024. PMID: 38396073 Free PMC article.

197

No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines.

Yalcinkaya A, Cavalli M, Cederholm A, Aranda-Guillén M, Behere A, Mildner H, Lakshmikanth T, Gonzalez L, Mugabo CH, Johnsson A, Ekwall O, Kämpe O, Bensing S, Brodin P, Hallberg P, Wadelius M, Landegren N. Yalcinkaya A, et al. NPJ Vaccines. 2024 Feb 22;9(1):42. doi: 10.1038/s41541-024-00829-9. NPJ Vaccines. 2024. PMID: 38388530 Free PMC article.

198

A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL^®) in infants.

Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Kawade A, Lalwani S, Ravi MD, Kamath V, Mahopatra J, Kulkarni G, Tayade D, Ramanan PV, Uttam KG, Rawal L, Gawande A, Kumar NR, Tiple N, Vagha J, Thakkar P, Khandgave P, Deshmukh BJ, Agarwal A, Dogar V, Gautam M, Jaganathan KS, Kumar R, Sharma I, Gairola S. Sharma H, et al. NPJ Vaccines. 2024 Feb 22;9(1):41. doi: 10.1038/s41541-024-00828-w. NPJ Vaccines. 2024. PMID: 38383584 Free PMC article.

199

Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV-workshop report.

Maciel M Jr, Amara RR, Bar KJ, Crotty S, Deeks SG, Duplessis C, Gaiha G, McElrath MJ, McMichael A, Palin A, Rutishauser R, Shapiro S, Smiley ST, D'Souza MP. Maciel M Jr, et al. NPJ Vaccines. 2024 Feb 21;9(1):39. doi: 10.1038/s41541-024-00818-y. NPJ Vaccines. 2024. PMID: 38383616 Free PMC article.

200

Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine.

Alleva DG, Feitsma EA, Janssen YF, Boersma HH, Lancaster TM, Sathiyaseelan T, Murikipudi S, Delpero AR, Scully MM, Ragupathy R, Kotha S, Haworth JR, Shah NJ, Rao V, Nagre S, Ronca SE, Green FM, Shaw SA, Aminetzah A, Kruijff S, Brom M, van Dam GM, Zion TC. Alleva DG, et al. NPJ Vaccines. 2024 Feb 21;9(1):40. doi: 10.1038/s41541-024-00830-2. NPJ Vaccines. 2024. PMID: 38383578 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,033 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,033 results

Results by year